[{"id":"dea5532c-b3c0-418a-829d-11fe7b2663af","acronym":"CAR2BRAIN","url":"https://clinicaltrials.gov/study/NCT03383978","created_at":"2021-01-18T16:41:54.714Z","updated_at":"2024-07-02T16:35:12.539Z","phase":"Phase 1","brief_title":"Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma","source_id_and_acronym":"NCT03383978 - CAR2BRAIN","lead_sponsor":"Johann Wolfgang Goethe University Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezabenlimab (BI 754091) • HER2 t-haNK"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 12/01/2017","start_date":" 12/01/2017","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-03-27"}]